Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Moderate Buy” from Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.3333.

Several brokerages have recently weighed in on RVPH. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. Chardan Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. D. Boral Capital reissued a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Finally, Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th.

Reviva Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:RVPH opened at $0.26 on Friday. The firm has a market capitalization of $29.92 million, a PE ratio of -0.57 and a beta of 0.06. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $1.88. The business’s 50 day moving average is $0.38 and its 200-day moving average is $0.46.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. On average, sell-side analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. 683 Capital Management LLC bought a new position in Reviva Pharmaceuticals in the 2nd quarter valued at $381,000. Persistent Asset Partners Ltd increased its stake in shares of Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after buying an additional 480,864 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 87.6% in the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after buying an additional 489,711 shares during the last quarter. Millennium Management LLC lifted its position in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Reviva Pharmaceuticals during the 2nd quarter worth about $1,026,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.